Sequential surgery following Yttrium-90 resin microspheres combined with targeted therapy and immunotherapy for primary hepatocellular carcinoma: a case report
Abstract Primary hepatocellular carcinoma (HCC) is a prevalent malignancy in China, often diagnosed at intermediate to advanced stages, limiting the feasibility of curative surgical resection. Yttrium-90 selective internal radiation therapy (90Y-SIRT) has emerged as a novel treatment demonstrating p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03014-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Primary hepatocellular carcinoma (HCC) is a prevalent malignancy in China, often diagnosed at intermediate to advanced stages, limiting the feasibility of curative surgical resection. Yttrium-90 selective internal radiation therapy (90Y-SIRT) has emerged as a novel treatment demonstrating potential for prolonging survival and inducing clinical remission in HCC patients. Its efficacy and safety have been progressively validated in clinical settings. This report describes a middle-aged male patient diagnosed with HCC accompanied by portal vein tumor thrombus. The treatment regimen comprised oral lenvatinib, intravenous sintilimab, and 90Y-SIRT. Successful sequential surgery was performed 7 months after 90Y-SIRT, and a 6-week follow-up showed no significant abnormalities. This case suggests that 90Y-SIRT, combined with other therapies, may be effective for patients with intermediate to advanced stage HCC. |
|---|---|
| ISSN: | 2730-6011 |